INTERNATIONAL PATENT: JANSSEN BIOTECH, INC. FILES APPLICATION FOR "COMBINATION OF TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3 AND AN ANTI-CD38 ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMA"

GENEVA, April 18 -- JANSSEN BIOTECH, INC. (800/850 Ridgeview DriveHorsham, Pennsylvania 19044) filed a patent application (PCT/IB2025/060306) for "COMBINATION OF TRISPECIFIC ANTIBODY TARGETING BCMA, GPRC5D AND CD3, AND AN ANTI-CD38 ANTIBODY FOR THE TREATMENT OF MULTIPLE MYELOMA" on Oct 10, 2025. With publication no. WO/2026/078659, the details related to the patent application was published on Apr 16, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LEE, Sangmin (c/o Janssen Research & Development, LLC920 US Route 202PO Box 300Raritan, New Jersey 08869), DASKALAKIS, Nikki (c/o Janssen Researc...